- Home
- CVKD
as 12-20-2024 4:00pm EST
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 20.8M | IPO Year: | 2023 |
| Target Price: | $46.00 | AVG Volume (30 days): | 79.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.40 - $32.55 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
Zacks Small Cap Research
a month ago
CVKD: Recent Financings Raise $9.8 Million…
PR Newswire
a month ago
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
PR Newswire
a month ago
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
PR Newswire
2 months ago
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
PR Newswire
2 months ago
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Simply Wall St.
2 months ago
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate
PR Newswire
2 months ago
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
Compare CVKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.